Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBC.1.3.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBC.1.3.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JN.11.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.11.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.11.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XDLNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDLNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XDLNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
JN.17NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.17NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
JN.17NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.29.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.29.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.29.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.29.2 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-1668.53US
AY.29.2 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.29.2 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-3660.47China
BC.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BC.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BC.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.10.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.10.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.10.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.3.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.3.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.3.13NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.3.13NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.3.13NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.3.9NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.3.9NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.3.9NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.10.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.10.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.10.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.56NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.56NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.56NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.29NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.29NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.29NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.10NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.10NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.10NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.501NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.501NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.501NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.226NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.226NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.226NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used